{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:43:00Z","timestamp":1759405380542,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002641","name":"Konkuk University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002641","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["2020M3A9I2107885"],"award-info":[{"award-number":["2020M3A9I2107885"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.05.071","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:50:14Z","timestamp":1686833414000},"page":"4787-4797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection"],"prefix":"10.1016","volume":"41","author":[{"given":"Deok-Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-6576","authenticated-orcid":false,"given":"Jiho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-3712","authenticated-orcid":false,"given":"Sungsu","family":"Youk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jei-hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-ye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-seon","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha-na","family":"Youn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-bin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyukchae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lah","family":"Mouhamed Abdallah Amal Abdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pil-Gu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kee-Jong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Seon","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2023","series-title":"Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). StatPearls","author":"Aleem","key":"10.1016\/j.vaccine.2023.05.071_b0005"},{"key":"10.1016\/j.vaccine.2023.05.071_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241875","article-title":"Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study","volume":"16","author":"Dixon","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.05.071_b0015","article-title":"Genomic characterization of a novel SARS-CoV-2","volume":"19","author":"Khailany","year":"2020","journal-title":"Gene Rep"},{"key":"10.1016\/j.vaccine.2023.05.071_b0020","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.05.071_b0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.vaccine.2023.05.071_b0030","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2023.05.071_b0035","article-title":"SARS-COV-2 variants: differences and potential of immune evasion","volume":"11","author":"Hirabara","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2023.05.071_b0040","article-title":"BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2","author":"Vogel","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2023.05.071_b0045","article-title":"SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness","author":"Corbett","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2023.05.071_b0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.05.071_b0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.05.071_b0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.20506\/rst.19.2.1231","article-title":"Newcastle disease and other avian paramyxoviruses","volume":"19","author":"Alexander","year":"2000","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.vaccine.2023.05.071_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/1297-9716-42-122","article-title":"Virulence of Newcastle disease virus: what is known so far?","volume":"42","author":"Dortmans","year":"2011","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2023.05.071_b0070","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2246","article-title":"Zoonotic potential of Newcastle disease virus: old and novel perspectives related to public health","volume":"32","author":"Ul-Rahman","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.05.071_b0075","first-page":"14","article-title":"Development and scalable production of Newcastle disease virus-vectored vaccines for human and veterinary use","author":"Fulber","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.05.071_b0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4939-6964-7_10","article-title":"Reverse genetics of Newcastle disease virus","volume":"1602","author":"Cardenas-Garcia","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2023.05.071_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083161","article-title":"Immunization with a thermostable newcastle disease virus K148\/08 strain originated from wild mallard duck confers protection against lethal viscerotropic velogenic newcastle disease virus infection in chickens","volume":"8","author":"Jeong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.05.071_b0090","article-title":"Live recombinant NDV-vectored H5 vaccine protects chickens and domestic ducks from lethal infection of the highly pathogenic H5N6 avian influenza virus","volume":"8","author":"Lee","year":"2021","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.vaccine.2023.05.071_b0095","unstructured":"OIE. Chapter 3.3.4: Avian influenza. OIE Terrestrial Manual; 2021."},{"key":"10.1016\/j.vaccine.2023.05.071_b0100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints 12","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.071_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26499-y","article-title":"A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.05.071_b0110","article-title":"Newcastle disease virus-like particles displaying prefusion-stabilized SARS-CoV-2 spikes elicit potent neutralizing responses","volume":"9","author":"Yang","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.05.071_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103132","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","volume":"62","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.05.071_b0120","article-title":"A Newcastle Disease Virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine","volume":"8","author":"Sun","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.05.071_b0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.05.071_b0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: from SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2023.05.071_b0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7150\/ijbs.52569","article-title":"Current advances in the development of SARS-CoV-2 vaccines","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.vaccine.2023.05.071_b0140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40545-022-00411-5","article-title":"Management of COVID-19 vaccines cold chain logistics: a scoping review","volume":"15","author":"Fahrni","year":"2022","journal-title":"J Pharm Policy Practice"},{"key":"10.1016\/j.vaccine.2023.05.071_b0145","article-title":"Recent advances in subunit vaccine carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.05.071_b0150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.05.071_b0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.05.071_b0160","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2023.05.071_b0165","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2020.12.018","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2019","volume":"39","author":"Sparrow","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.071_b0170","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.vaccine.2019.10.074","article-title":"Genetic stability of a Newcastle disease virus vectored infectious laryngotracheitis virus vaccine after serial passages in chicken embryos","volume":"38","author":"Yu","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.071_b0175","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJMra2200583","article-title":"Understanding vaccine safety and the roles of the FDA and the CDC","volume":"386","author":"Meissner","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.071_b0180","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1073\/pnas.0703584104","article-title":"Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens","volume":"104","author":"DiNapoli","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.05.071_b0185","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.12998\/wjcc.v7.i16.2143","article-title":"Application of Newcastle disease virus in the treatment of colorectal cancer","volume":"7","author":"Song","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.vaccine.2023.05.071_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/v8070183","article-title":"Newcastle Disease virus as a vaccine vector for Development of Human and Veterianry vaccines","volume":"8","author":"Kim","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.05.071_b0195","article-title":"Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: interim results of a non-randomized open label phase I trial in Mexico","author":"Ponce-de-Le\u00f3n","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2023.05.071_b0200","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049632","article-title":"Comparison of the pathogenesis of SARS-CoV-2 infection in K18-hACE2 mouse and Syrian golden hamster models","volume":"15","author":"Jeong","year":"2022","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.vaccine.2023.05.071_b0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24377-1","article-title":"SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.05.071_b0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41541-022-00440-w","article-title":"Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice","volume":"7","author":"Lazaro-Frias","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2023.05.071_b0215","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41423-021-00774-w","article-title":"Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects","volume":"19","author":"Zheng","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2023.05.071_b0220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12985-016-0568-5","article-title":"Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry","volume":"13","author":"Wang","year":"2016","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2023.05.071_b0225","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.05.071_b0230","first-page":"10","article-title":"VSV-based vaccines reduce virus shedding and viral load in hamsters infected with SARS-CoV-2 variants of concern","author":"O'Donnell","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.05.071_b0235","first-page":"13","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","author":"van Doremalen","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2023.05.071_b0240","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/emph\/eoac010","article-title":"Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution","volume":"10","author":"Amicone","year":"2022","journal-title":"Evol Med Public Health"},{"key":"10.1016\/j.vaccine.2023.05.071_b0245","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1039\/D2AN00028H","article-title":"Detection of SARS CoV-2 coronavirus omicron variant with mass spectrometry","volume":"147","author":"Mann","year":"2022","journal-title":"Analyst"},{"key":"10.1016\/j.vaccine.2023.05.071_b0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant","volume":"28","author":"Gruell","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.05.071_b0255","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.crimmu.2022.10.001","article-title":"Mucosal delivery of RNA vaccines by Newcastle disease virus vectors","volume":"3","author":"Garc\u00eda-Sastre","year":"2022","journal-title":"Curr Res Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:32Z","timestamp":1759404452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":51,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23006412"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}